fingolimod hydrochloride has been researched along with calpain in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (calpain) | Trials (calpain) | Recent Studies (post-2010) (calpain) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 7,019 | 25 | 2,422 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morley, SJ; Pain, VM | 1 |
1 other study(ies) available for fingolimod hydrochloride and calpain
| Article | Year |
|---|---|
Proteasome inhibitors and immunosuppressive drugs promote the cleavage of eIF4GI and eIF4GII by caspase-8-independent mechanisms in Jurkat T cell lines.
Topics: Acetylcysteine; Apoptosis; Calpain; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cyclosporine; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Eukaryotic Initiation Factor-4G; fas Receptor; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Jurkat Cells; Leupeptins; Multienzyme Complexes; Peptide Fragments; Peptide Initiation Factors; Propylene Glycols; Proteasome Endopeptidase Complex; Sphingosine; T-Lymphocytes | 2001 |